Acquisition of invasive capacity was first evident in Trp53(−/−) tumours at 12 weeks, in contrast to the Trp53 mutants, which only displayed EMT at endpoint, both through protein staining (vimentin positivity Fig. 3) and gene expression (Fig. 6c). Here, VIM is linked to neoplasm.